Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Olanzapine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sunshine Biopharma Launches Olanzapine and Olanzapine ODT
Details : Olanzapine is a 5-HT2A/2C/D2R inhibitor, indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders.
Product Name : Zyprexa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 21, 2025
Lead Product(s) : Olanzapine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HEC88473
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Apollo Therapeutics
Deal Size : $938.0 million
Deal Type : Licensing Agreement
Apollo Licenses FGF21/GLP-1 Agonist from Sunshine Lake for Multi-Indications
Details : The agreement aims for the development of APL-18881 (HEC88473), a bi-specific fusion protein developed by Sunshine Lake that agonizes FGF21 and GLP-1 receptors in patients with type 2 diabetes.
Product Name : APL-18881
Product Type : Other Large Molecule
Upfront Cash : $12.0 million
December 11, 2024
Lead Product(s) : HEC88473
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Apollo Therapeutics
Deal Size : $938.0 million
Deal Type : Licensing Agreement
Lead Product(s) : K1.1 mRNA
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sunshine Biopharma Reports K1.1 mRNA Breakthrough for Liver Cancer Therapy
Details : K1.1, are readily adaptable for delivery into patients using the mRNA vaccine technology, it is currently being investigated as a novel therapeutic agent for human hepatocellular carcinoma.
Product Name : K1.1 mRNA
Product Type : Vaccine
Upfront Cash : Inapplicable
December 02, 2024
Lead Product(s) : K1.1 mRNA
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ursodeoxycholic Acid
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sunshine Biopharma Launches a New Generic Prescription Drug
Details : Ursodiol is indicated for the treatment of patients with Primary Biliary Cirrhosis. It inhibits the absorption of cholesterol and the secretion of cholesterol.
Product Name : Urso DS-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 22, 2024
Lead Product(s) : Ursodeoxycholic Acid
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Adva-27a
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Jewish General Hospital
Deal Size : Undisclosed
Deal Type : Agreement
Details : The research effort will be focused on advancing the development of Sunshine Biopharma’s Adva-27a anticancer compound through IND-enabling studies. At any time the research results become conclusive, company will proceed to conducting a Phase I clinica...
Product Name : Adva-27a
Product Type : Protein
Upfront Cash : Undisclosed
October 02, 2023
Lead Product(s) : Adva-27a
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Jewish General Hospital
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : K1.1
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The Company’s collaboration partner will prepare two LNP formulations (K1.1a and K1.1b) of Sunshine Biopharma’s in-house developed antineoplastic mRNA, K1.1.
Product Name : K1.1
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
November 16, 2022
Lead Product(s) : K1.1
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Adva-27a
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Adva-27a, a GEM-difluorinated C-glycoside derivative of Podophyllotoxin, targeted for various forms of cancer, is able to destroy cancer cells through the inhibition of a key cell-cycle enzyme called Topoisomerase II.
Product Name : Adva-27a
Product Type : Protein
Upfront Cash : Inapplicable
May 04, 2022
Lead Product(s) : Adva-27a
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Recently communicated mRNA molecules GEM-difluorinated C-glycoside Derivative of Podophyllotoxin found in pre-clinical trials is effective at destroying cancer cells grown in culture.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 25, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SBFM-PL4
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : University of Arizona
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The development of the PLpro inhibitor, SBFMPL4, is currently continuing at the University of Georgia. At the University of Arizona, the research effort will focus on determining the in vivo safety, pharmacokinetics, and dose selection properties.
Product Name : SBFM-PL4
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 25, 2022
Lead Product(s) : SBFM-PL4
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : University of Arizona
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Adva-27a
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Adva-27a is a unique anticancer compound targeted for multidrug resistant cancer. This newly issued patent contains new subject matter and extends the proprietary protection of Adva-27a in Europe until 2033.
Product Name : Adva-27a
Product Type : Protein
Upfront Cash : Inapplicable
November 03, 2021
Lead Product(s) : Adva-27a
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable